STLN
Starling Oncology Inc.
STLN | NASDAQ
$6.49
-$0.04 (-0.61%)
Nov 2, 2026, 10:39 AM ET · Market open
TTM Period Ending | Q2 2026 Jun 30, 2026 | Q1 2026 Mar 31, 2026 | Q4 2025 Dec 31, 2025 | Q3 2025 Sep 30, 2025 |
|---|---|---|---|---|
Net Income | -36.29M | -26.5M | -24.01M | -16.5M |
Depreciation & Amortization | 6.81M | 4.97M | 3.36M | 1.72M |
Stock-Based Compensation | 5.1M | 4.03M | 2.34M | 1.02M |
Other Working Capital | 6.45M | 1.67M | -2.19M | 528K |
Other Non-Cash Items | 8.01M | 3.49M | 7.44M | 7.3M |
Deferred Income Tax | n/a | n/a | n/a | n/a |
Change in Working Capital | 16.71M | 2.41M | 1.48M | -6.17M |
Operating Cash Flow | 328K | -11.61M | -9.4M | -12.63M |
Capital Expenditures | -3.61M | -2.71M | -1.66M | -604K |
Cash Acquisitions | n/a | n/a | n/a | n/a |
Purchase of Investments | n/a | n/a | n/a | n/a |
Sales Maturities Of Investments | n/a | n/a | n/a | n/a |
Other Investing Acitivies | n/a | n/a | n/a | n/a |
Investing Cash Flow | -3.61M | -2.71M | -1.66M | -604K |
Debt Repayment | -34K | -26K | -17K | -8K |
Common Stock Repurchased | n/a | n/a | n/a | n/a |
Dividend Paid | n/a | n/a | n/a | n/a |
Other Financial Acitivies | -1.15M | -845K | -585K | -235K |
Financial Cash Flow | 14.09M | 14.31M | 14.33M | 10.6M |
Net Cash Flow | 10.8M | -12K | 3.27M | -2.63M |
Free Cash Flow | -3.29M | -14.32M | -11.06M | -13.23M |
Adj. Free Cash Flow | -8.38M | -18.35M | -13.4M | -14.26M |
Maintenance CapEx | -3.61M | n/a | n/a | n/a |
Growth CapEx | n/a | n/a | n/a | n/a |
Owner Earnings | -3.29M | n/a | n/a | n/a |
Add to Watchlist
Select watchlists to add or remove STLN